摘要
近期新型冠状病毒(SARS-CoV-2)感染所致肺炎疫情的爆发给各国公共卫生和治理带来了重大挑战。目前临床上尚无针对SARS-CoV-2的特效药,采用的多为既往治疗严重急性呼吸综合征(SARS)和中东呼吸综合症(MERS)的抗病毒药物。本文旨在对有关抗病毒药物及其药代动力学特征进行整理和分析,并对其开展治疗药物监测(TDM)的特点和必要性进行探讨,从而为抗SARS-CoV-2治疗中的用药安全提供参考。
The recent outbreak of pneumonia caused by new coronavirus(SARS-CoV-2)infection has brought major challenges to public health and governance in various countries.At present,there is no clinically specific drug for SARS-CoV-2,and most of the antiviral drugs used are drugs for the treatment of severe acute respiratory syndrome(SARS)and Middle East Respiratory Syndrome(MERS).This article aims to organize and analyze the antiviral drugs and their pharmacokinetic characteristics,and to discuss the characteristics and necessity of therapeutic drug monitoring(TDM),so as to provide a reference for the safety of anti-SARSCoV-2 treatment.
作者
张露
林良沫
刘可可
黄娅敏
黄行行
杨永榆
肖坚
ZHANG Lu;LIN Liangmo;LIU Keke;HUANG Yamin;HUANG Xingxing;YANG Yongyu;XIAO Jian(Department of Pharmacy,Xiangya Hospital,Central South University;National Medical Center for Geriatrics,Xiangya Hospital,Central South University,Laboratory for Rational and Safe Use of Elderly,Changsha 410008,Hunan,China;Department of Pharmacy,Hainan Provincial People's Hospital,Haikou 570311,Hainan,China;Beihai Second People's Hospital,Beihai 536000,Guangxi,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2020年第5期566-575,共10页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家自然科学基金面上项目(81974513)。
关键词
新型冠状病毒肺炎
抗病毒药物
治疗药物监测
不良反应
药代动力学
new coronavirus pneumonia
antiviral drugs
therapeutic drug monitoring
adverse reactions
pharmacokinetics
